

Mexico City, September 27th, 2013

GENOMMA LAB ANNOUNCES ACQUISITION OF A PACKAGE OF OVER-THE-COUNTER BRANDS

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) (“Genomma Lab” or “the Company”) announced today that it has acquire a package of seven over-the-counter (“OTC”) brands to be incorporated into its portfolio.

The Company signed different acquisition contracts and licensing agreements among which are: with *Representaciones e Investigaciones Médicas* for the **Oxigricol** brand, with *AstraZeneca* for the **Mopral**, **Xyloproct** and **Xyloderm** brands, with *Laboratorios Imperiales* for the brand **Estomacurool**, and with *Laboratorios Columbia Comercial* for the **Passiflorine** and **Ah-Micol** brands.

Each brand has a strong presence in the categories in which it participates: **Oxigricol** participates in the anti-flu and cough without infection category and with a patented formula and has sales of approximately \$24 million pesos; **Mopral** participates in the acid inhibitors category and **Estomacurool** participates in the anti-peptic ulcers category, both with joint sales of above \$10 million pesos; **Xyloproct** participates in the anti-hemorrhoids category with sales of more than \$46 million pesos; **Xyloderm** participates in the corticoid steroids topical with anti-bacterial medicines with sales close to \$10 million pesos; **Passiflorine** participates in the hypnotics and sedatives category with sales of \$12 million pesos; and, **Ah-Micol** participates in the anti-parasites category with sales of around \$3 million pesos.

With this transaction, the Company consolidates its presence in the OTC market, and strengthens its leadership positioning in the anti-flu and cough, acid inhibitors, anti-hemorrhoids, corticoid steroids topical medicines and sedatives categories, while entering the anti-parasites category.

The transaction amounts to \$252.1 million pesos, representing a multiple of 2.39 times sales in the past 12 months to August 2013, according to IMS Health. The transaction will be financed with the long term loans the Company has.

“We are very pleased with the acquisition of this package of brands, as it further strengthens the Company’s presence and leadership in the OTC market in Mexico, while expanding its objective of becoming one of the leaders of this market across Latin America,” stated Rodrigo Herrera, Chief Executive Officer and Chairman of Genomma Lab.

Contact:

Investor Relations

Tel: +52 (55) 5081 0000 Ext. 5106

E-mail: inversion@genommalab.com

In New York: Grayling USA, Lucía Domville

Tel: +1 (646) 284-9416

E-mail: genommalab@grayling.com

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model.

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.